Welcome to our dedicated page for Pacific Software news (Ticker: PFSF), a resource for investors and traders seeking the latest updates and insights on Pacific Software stock.
Pacific Software Inc. (PFSF) delivers advanced skincare solutions through patented cosmeceutical technologies and science-backed dietary supplements. This news hub provides investors and industry professionals with essential updates on product innovations, financial milestones, and strategic partnerships driving the company's growth in aesthetic medicine.
Access real-time announcements about Dermatrix technology developments, clinical trial results, and academic collaborations with institutions like the University of California. Our curated news collection simplifies tracking regulatory approvals, market expansions, and scientific breakthroughs in peptide inhibitor applications for wound healing and cosmetic enhancements.
Key updates include earnings reports, licensing agreements, executive appointments, and research publications. Bookmark this page for streamlined monitoring of PFSF's progress in commercializing IDE-blocking solutions and expanding its presence in therapeutic skincare markets.
Pacific Software Inc. (OTC:PFSF) has appointed Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA). Dr. Schiestl, a distinguished scientist with over 200 peer-reviewed publications and 16 patents, brings extensive expertise in molecular toxicology, cancer prevention, and genomics. His research focuses on genetic stability and strategies to prevent genetic diseases and cancer, aligning with Pacific Software's mission to develop innovative skincare products and science-based dietary supplements.
Dr. Schiestl's background includes positions at Harvard School of Public Health and UCLA, where he is currently Professor Emeritus. His work on oxidative stress and its health impacts is particularly relevant to Pacific Software's objectives. CEO Harrysen Mittler expressed enthusiasm about Dr. Schiestl's potential contributions to advancing the company's cosmeceutical technology and supplement offerings.
Pacific Software announced the acquisition of a dietary supplement designed to support brain health and memory, marketed as SuppleMEM AD™ and A.L.Z. Defense™.
The formula, tested by leading Alzheimer's researchers, has been sold for over 8 years. The company is obtaining quotes to manufacture this product in the USA and Mexico, targeting distribution in the third quarter of 2024.
This acquisition aligns with Pacific's strategy to diversify into health and skin care products. The core formula, a blend of natural ingredients, has shown positive results in NIH-funded studies at UC Irvine and the University of Kentucky.
The company expects revenue from retail and wholesale channels. Dr. Leissring resigned as president on June 18, 2024.
Pacific Software announced its acquisition of a science-based dietary supplement focused on brain health and memory function, sold under the brand names SuppleMEM AD™ and A.L.Z. Defense™. This acquisition marks Pacific's expansion beyond its previous focus on skin care and wound healing. CEO Harrysen Mittler stated the product has been profitable for over 8 years, and studies funded by the NIH at the University of California, Irvine, and the University of Kentucky have validated its effectiveness. Pacific's President, Dr. Malcolm Leissring, emphasized that proceeds will support the AD Foundation's Alzheimer’s prevention initiatives.
Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.
The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.
The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.
Pacific Software Inc. (PFSF) announced the acquisition of certain assets from Dreamaderm Inc., including a patented cosmeceutical technology called Dermatrix. Dermatrix boosts collagen production by preserving insulin in the skin, offering a wide range of dermatological applications. The technology was developed by Dr. Malcolm A. Leissring and has the potential to revolutionize the cosmetics and skin care industry.
Pacific Software, Inc. (OTCPINK:PFSF) has issued a letter to shareholders highlighting its achievements and future plans. In 2021, the company undertook significant restructuring and made strides in development with multiple joint ventures and acquisitions. Key successes include launching partnerships with Lincoln Clark and Raffaele Gallo, along with a 51% acquisition of a World of Beer tavern. Looking ahead, the company anticipates several new restaurant openings and a rebranding to align with its growth strategy.
Pacific Software, Inc. (OTC PINK:PFSF) announced a debt restructuring of approximately $3,000,000 to enhance its capital structure ahead of its growth initiatives for 2022. The restructuring moves legacy notes from a fixed percentage to a fixed price conversion rate, eliminating liability premiums and interest expenses. This adjustment is expected to simplify accounting and improve financial transparency. The company aims to launch several new restaurant locations and brands soon, indicating a robust growth strategy.
Pacific Software, Inc. (OTCPINK:PFSF) is repositioning to enter the fast casual restaurant market, projected to grow from $125.6 billion in 2019 to $209.1 billion by 2027, at a CAGR of 10.6%.
To spearhead this transition, the company has appointed Isaac Onn as CEO and Michael Finkelstein as COO, both with extensive industry experience. Their strategy includes acquiring restaurant chains affected by the Covid-19 pandemic, aiming to build a diverse cash flow portfolio. The company will also undergo a name change and is launching a new website soon.
